NASDAQ:CLLS - Cellectis Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $30.04 -0.05 (-0.17 %) (As of 07/22/2018 04:00 PM ET)Previous Close$30.04Today's Range$29.7150 - $30.4152-Week Range$21.25 - $38.85Volume89,414 shsAverage Volume123,914 shsMarket Capitalization$1.25 billionP/E Ratio-10.81Dividend YieldN/ABeta1.88 Company ProfileFinancialsAnalyst RatingsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Receive CLLS News and Ratings via Email Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:CLLS CUSIPN/A Webwww.cellectis.com Phone33-1-81-69-16-00 Debt Debt-to-Equity RatioN/A Current Ratio7.18 Quick Ratio7.17 Price-To-Earnings Trailing P/E Ratio-10.81 Forward P/E Ratio-11.60 P/E GrowthN/A Sales & Book Value Annual Sales$33.72 million Price / Sales37.06 Cash FlowN/A Price / CashN/A Book Value$7.96 per share Price / Book3.77 Profitability EPS (Most Recent Fiscal Year)($2.78) Net Income$-99,360,000.00 Net Margins-337.45% Return on Equity-37.45% Return on Assets-31.83% Miscellaneous Employees135 Outstanding Shares41,600,000Market Cap$1,249.81 Cellectis (NASDAQ:CLLS) Frequently Asked Questions What is Cellectis' stock symbol? Cellectis trades on the NASDAQ under the ticker symbol "CLLS." How were Cellectis' earnings last quarter? Cellectis SA (NASDAQ:CLLS) released its quarterly earnings results on Monday, May, 7th. The biotechnology company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.01. The biotechnology company earned $8.07 million during the quarter, compared to analyst estimates of $9.53 million. Cellectis had a negative return on equity of 37.45% and a negative net margin of 337.45%. View Cellectis' Earnings History. When is Cellectis' next earnings date? Cellectis is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Cellectis. What price target have analysts set for CLLS? 7 equities research analysts have issued 12-month target prices for Cellectis' shares. Their forecasts range from $20.00 to $73.00. On average, they expect Cellectis' stock price to reach $45.6667 in the next twelve months. This suggests a possible upside of 52.0% from the stock's current price. View Analyst Ratings for Cellectis. What is the consensus analysts' recommendation for Cellectis? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Cellectis' key competitors? Some companies that are related to Cellectis include Ablynx (ABLYF), China Biologic Products (CBPO), argenx (ARGX), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Repligen (RGEN), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO) and Solid Biosciences (SLDB). Who are Cellectis' key executives? Cellectis' management team includes the folowing people: Dr. André Choulika, Co-Founder, Chairman & CEO (Age 53)Dr. David J. D. Sourdive, Co-Founder, Exec. VP - Technical Operations and Director (Age 51)Mr. Eric Dutang, Chief Financial Officer (Age 44)Ms. Elsy Boglioli, Chief Operating Officer (Age 36)Mr. Jean Charles Epinat, Chief Technological Officer When did Cellectis IPO? (CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager. Has Cellectis been receiving favorable news coverage? Media headlines about CLLS stock have trended positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cellectis earned a coverage optimism score of 0.25 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 47.91 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. How do I buy shares of Cellectis? Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cellectis' stock price today? One share of CLLS stock can currently be purchased for approximately $30.04. How big of a company is Cellectis? Cellectis has a market capitalization of $1.25 billion and generates $33.72 million in revenue each year. The biotechnology company earns $-99,360,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Cellectis employs 135 workers across the globe. How can I contact Cellectis? Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected] MarketBeat Community Rating for Cellectis (NASDAQ CLLS)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 246 (Vote Outperform)Underperform Votes: 129 (Vote Underperform)Total Votes: 375MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?